New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition

Springer Health+ IME: Podcast to Practice
16/06/2025 23 min Temporada 7 Episodio 3
New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition

Listen "New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Kelly Gwathmey and Dr. Pushpa Narayanaswami discuss clinical evidence and practical considerations for integrating FcRn antagonists and complement inhibitors into the treatment of gMG.

More episodes of the podcast Springer Health+ IME: Podcast to Practice

Key Ketone Monitoring Updates and Highlights From the ADA 2025 Conference | S8E1 03/07/2025
Embracing gMG advances together: ensuring multidisciplinary collaboration 30/06/2025
Advances in gMG: implications for practice 24/06/2025
New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies 16/06/2025
Deep dive into targeted therapies: understanding IDH1-mutant AML treatments | S6E3 16/06/2025
Understanding gMG 10/06/2025
Voices of gMG: enhancing patient-centric care 03/06/2025
Advancing AML treatment: evidence-based regimens and guidelines for R/R AML management | S6E2 03/06/2025
Unveiling the mysteries of molecular testing in AML: a guide for oncologists | S6E1 20/05/2025
Key CGM Updates and Highlights From the 2025 Standards of Care in Diabetes Revision by the ADA | S3E4 17/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA